This is a positive operational catalyst for a $46M market cap clinical-stage biotech. Monitor for site activation announcements and patient dosing updates as the next catalysts. The DReAMzz study is designed to optimize Phase III design, so successful completion could reduce future trial costs and regulatory risk. No financial data was provided, so the impact is sentiment-driven.
Price Chart
Executive Summary
Incannex Healthcare announced the official commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep apnea (OSA). All 14 clinical trial sites have been identified, manufacturing of IHL-42X drug product is complete, import/export permits secured, and a global distribution partner onboarded. This is an operational milestone advancing a late-stage asset with prior FDA Fast Track designation, but no new clinical data or financial figures were released.
Key Facts
- DReAMzz clinical study for IHL-42X in obstructive sleep apnea officially commenced
- All 14 clinical trial sites identified; site contracting underway
- Manufacturing of IHL-42X drug product completed
- Import and export permits secured; global distribution partner onboarded
- IHL-42X previously granted FDA Fast Track designation for OSA
- Study designed as crossover dose optimization to de-risk Phase III pathway
- Follows positive Phase II RePOSA trial with statistically significant AHI reductions
Financial Impact
No financial figures disclosed; operational milestone with no revenue or earnings impact reported
Risk Factors
- Clinical-stage company with no approved products or revenue; high cash burn risk
- DReAMzz study results may not support Phase III design as expected
- Regulatory pathway remains uncertain despite Fast Track designation
- Potential dilutive financing needed to fund ongoing operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-056227 |
| Document: ea029029201ex99-1.htm | 0001213900-26-056227 |
| Document: 0001213900-26-056227-index-headers.html | 0001213900-26-056227 |
| Document: 0001213900-26-056227-index.html | 0001213900-26-056227 |
| Document: 0001213900-26-056227.txt | 0001213900-26-056227 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.62 (−18.89%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.62 (−30.13%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.62 (−18.13%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.62 (−28.61%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers